Press Release From The Cancer Institute of New Jersey
February 1, 2007
Contacts: Candace Botnick
The Cancer Institute of New Jersey
Robert Wood Johnson Medical School
The Cancer Institute of New Jersey Announces New Leadership
NEW BRUNSWICK — Peter S. Amenta, M.D, Ph.D., Interim Dean of UMDNJ-Robert Wood Johnson Medical School has announced the appointment of Joseph R. Bertino, MD, a world-class researcher and clinician, as the Interim Director of Robert Wood Johnson Medical School’s Cancer Institute of New Jersey (CINJ).
William N. Hait, MD, PhD, who has served as CINJ’s director since 1993, will step down. Under his leadership, The Cancer Institute of New Jersey successfully obtained cancer center designation from the National Cancer Institute in 1997. In 2002, it received the National Cancer Institute’s highest designation to become the 39th Comprehensive Cancer Center in the United States. CINJ is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center and just one of three in the New York metropolitan area.
“Under the direction of Dr. Joseph Bertino, The Cancer Institute of New Jersey will advance its leadership role throughout the state and the nation by providing excellent patient care, cutting edge research and ongoing education in the field of oncology,” said Dr. Amenta. “As one of the nation’s foremost cancer researchers he will lead with vision and dedication.”
Dr. Bertino will provide a seamless transition for CINJ and continue its mission of conducting state-of-the-art cancer research and providing exemplary patient care for all New Jerseyans. Since 2002, Dr. Bertino has served as Associate Director of CINJ and University Professor of Medicine and Pharmacology at UMDNJ-Robert Wood Johnson Medical School. He was appointed Chief Scientific Officer of CINJ in 2004. Prior to joining CINJ and UMDNJ, Dr. Bertino served as Chairman of the Molecular Pharmacology and Therapeutics Program, and Member and Co-head of the Program in Developmental Therapy and Clinical Investigation at Memorial Sloan-Kettering Institute for Cancer Research. From 1973 to 1986 Dr. Bertino served as Director of the Yale Comprehensive Cancer Center, including Director of the Center and Associate Director for Clinical Research. Dr. Bertino has been internationally recognized for his role in finding curative treatments for leukemia and lymphoma.
“With Drs. Joe Bertino and Arnie Levine, a pioneer in cancer research, The Cancer Institute of New Jersey can legitimately claim to be home to two of the greatest researchers in the history of cancer medicine,” stated Dr. Hait.
As testimony to Dr. Hait’s leadership style and vision, his colleagues at CINJ are well-positioned to continue the Cancer Institute’s stellar record of research, education, and patient care. CINJ’s faculty members are at the forefront in the war against cancer and are recognized by colleagues around the globe for their excellence in cancer research and cancer care. At CINJ, cancer research is supported by more than $93 million annually in research grants.
CINJ has grown from a dream in the early 1990’s to an NCI-designated Comprehensive Cancer Center. Today, CINJ sees over 72,000 patient visits annually. Patients at CINJ receive compassionate care and are assured of the most promising treatments. Through its extensive network of affiliated hospitals, CINJ has become a statewide resource providing the best cancer care available to all New Jerseyans.
“Under Dr. Hait’s leadership, CINJ has achieved its mission of creating a cancer center of extraordinary quality for the people of New Jersey and is extremely well positioned for the future under Dr. Bertino’s guidance,” said Robert Campbell, longtime chairman of the CINJ Board of Overseers.
Leadership Team of CINJ
Jospeh Bertino, M.D., Interim Director, CINJ and University Professor of Medicine and Pharmacology, UMDNJ-Robert Wood Johnson Medical School, joined CINJ in 2002 after holding several leadership positions at Memorial-Sloan Kettering Cancer Center and the Yale Comprehensive Cancer Center.
Arnold Rabson, M.D., Deputy Director, CINJ and Professor of Molecular Genetics, Microbiology and Immunology and Professor of Pathology at UMDNJ-Robert Wood Johnson Medical School, is a world-class leader in cancer research who joined Robert Wood Johnson Medical School in the early 1990s from the National Institutes of Health.
Molly Gabel, M.D., Deputy Director for Extramural Affairs, CINJ and Associate Professor of Radiation Oncology, UMDNJ-Robert Wood Johnson Medical School, joined CINJ in 2003 from the Josephine Ford Cancer Center at the Henry Ford Health System in Detroit Michigan. She is the executive in charge of the CINJ Network of hospitals, CINJOG and community outreach - showing CINJ’s commitment to the community.
Joseph Aisner, M.D., Chief Medical Officer, CINJ and Professor of Medicine and Environmental and Community Medicine, UMDNJ-Robert Wood Johnson Medical School.
David August, M.D., Chief, Division of Surgical Oncology and Chief Academic Officer, CINJ and Professor of Surgery, UMDNJ-Robert Wood Johnson Medical School.
Regina Cunningham, Ph.D., RN, AOCN, Chief Nursing Officer, CINJ and Assistant Professor, Family Medicine, UMDNJ-Robert Wood Johnson Medical School.
Robert DiPaola, M.D., Chief, Division of Medical Oncology, CINJ and Professor of Medicine, UMDNJ-Robert Wood Johnson Medical School.
Michael A. Gallo, Ph.D., Associate Director for Population Science, CINJ and Professor of Environmental and Occupational Medicine, UMDNJ-Robert Wood Johnson Medical School.
Bruce Haffty, M.D., Chair, Dept. of Radiation Oncology, CINJ and UMDNJ-Robert Wood Johnson Medical School.
Barton Kamen, M.D., Ph.D., Chief, Division of Pediatric Hematology/Oncology and Professor of Pediatrics and Pharmacology, UMDNJ-Robert Wood Johnson Medical School.
Edmund Lattime, Ph.D., Associate Director for Education and Training and Professor of Surgery, UMDNJ-Robert Wood Johnson Medical School.
Michael Reiss, M.D., Associate Director for Translational Research and Professor of Medicine, UMDNJ-Robert Wood Johnson Medical School.
Lorna Rodriguez, M.D., Ph.D., Chief, Division of Gynecologic Oncology and Professor of Obstetrics, Gynecology and Reproductive Sciences, UMDNJ-Robert Wood Johnson Medical School.
Eric Rubin, M.D., Associate Director for Clinical Science, and Professor of Medicine and Pharmacology, UMDNJ-Robert Wood Johnson Medical School.
Mary Todd, D.O., Chief Operating Officer, CINJ and Professor of Medicine, UMDNJ-Robert Wood Johnson Medical School.
Eileen White, Ph.D., Associate Director for Basic Science, CINJ and Professor of Department of Molecular Biology and Biochemistry, Rutgers, The State University of New Jersey.
About The Cancer Institute of New Jersey
The Cancer Institute of New Jersey is New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, and is dedicated to improving the prevention, detection, treatment and care of patients with cancer. CINJ’s physician-scientists engage in translational research, transforming their laboratory discoveries into clinical practice-quite literally bringing research to life. The Cancer Institute of New Jersey is a Center of Excellence of the UMDNJ-Robert Wood Johnson Medical School. To support CINJ, please call The Cancer Institute of New Jersey Foundation at 1-888-333-CINJ. The Cancer Institute of New Jersey Network is comprised of hospitals throughout the state and provides a mechanism to rapidly disseminate important discoveries into the community. Partner Hospitals: Robert Wood Johnson University Hospital, Atlantic Health System (Morristown Memorial Hospital, Mountainside Hospital, Overlook Hospital). Affiliate Hospitals: Bayshore Community Hospital, CentraState Healthcare System, Cooper University Hospital (CINJ at Cooper),* Jersey Shore University Medical Center, JFK Medical Center, Monmouth Medical Center, Raritan Bay Medical Center, Robert Wood Johnson University Hospital at Hamilton (CINJ-Hamilton), Saint Peter’s University Hospital, Somerset Medical Center, Southern Ocean County Hospital, The University Hospital/UMDNJ-New Jersey Medical School,* and University Medical Center at Princeton. *Academic Affiliate
UMDNJ is the nation's largest free-standing public health sciences university with more than 5,500 students attending the state's three medical schools, its only dental school, a graduate school of biomedical sciences, a school of health related professions, a school of nursing and its only school of public health, on five campuses. Last year, there were more than two million patient visits to UMDNJ facilities and faculty at campuses in Newark, New Brunswick/Piscataway, Scotch Plains, Camden and Stratford. UMDNJ operates University Hospital, a Level I Trauma Center in Newark, and University Behavioral HealthCare, a mental health and addiction services network.